PD-L1 IHC 22C3 pharmDx: Analytical validation on cervical cancer specimens

被引：0
|
作者：
Musser, J. [1 ]
Evans, T. [1 ]
Posch, A. [1 ]
Vasquez, J. [1 ]
Tabuena-Frolli, S. [1 ]
Apostolaki, A. [1 ]
Kulangara, K. [1 ]
机构：
[1] Agilent Technol, Santa Clara, CA USA
来源：
VIRCHOWS ARCHIV | 2022年 / 481卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
PS-08-011
引用
收藏
页码：S109 / S109
页数：1
相关论文
共 50 条
  • [21] Comparison of PD-L1 Expression Using 2 Validated PD-L1 IHC 22C3 pharmDx Methods in Non-Small Cell Lung Cancer in a Routine Hospital Setting
    Skov, Birgit G.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2021, 29 (01) : 49 - 55
  • [22] PD-L1 assessment in oesophageal and gastro-oesophageal adenocarcinoma with PD-L1 IHC 22C3 pharmDx and PD-L1 IHC 28-8 pharmDx assays on Autostainer Link 48: The University Hospitals Birmingham experience over a period of 18 months
    O'Sullivan, B.
    Taniere, P.
    Charles, K.
    Pritchard, J.
    Gawthorpe, S.
    Thompson, J.
    Dowds, J.
    Diaz-Cano, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S868 - S868
  • [23] High concordance of the PD-L1 22C3 antibody LDT protocol on BenchMark XT compared to the PD-L1 IHC 22C3 pharmDx kit for urothelial carcinoma (UC) and head and neck squamous cell carcinoma (HNSCC)
    Vainer, G.
    Neuman, T.
    Fellig, Y.
    Meir, K.
    Hirshoren, N.
    Gofrit, O.
    Huang, L.
    Juco, J.
    Bal, T.
    VIRCHOWS ARCHIV, 2019, 475 : S95 - S95
  • [24] Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays
    Chapel, David B.
    Stewart, Rachel
    Furtado, Larissa V.
    Husain, Aliya N.
    Krausz, Thomas
    Deftereos, Georgios
    HUMAN PATHOLOGY, 2019, 87 : 11 - 17
  • [25] PD-L1 Expression Harmonization in Gastric Cancer Using 22C3 PharmDx and SP263 Assays
    Dabbagh, Tamara Z.
    Sughayer, Maher A.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2021, 29 (06) : 462 - 466
  • [26] Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications
    Vainer, Gilad
    Huang, Lingkang
    Emancipator, Kenneth
    Nuti, Shanthy
    PLOS ONE, 2023, 18 (06):
  • [27] PD-L1 expression in ovarian clear cell carcinoma using the 22C3 pharmDx assay
    Gao, Yike
    Pan, Boju
    Jia, Hongbao
    Zhang, Yang
    Wang, Shu
    Wang, Yuming
    Zhang, Sumei
    Li, Mei
    Wang, Anqi
    Wang, Xiaoxi
    Zhao, Kun
    Zhang, Zixin
    Sun, Jian
    Guo, Dan
    Liang, Zhiyong
    DIAGNOSTIC PATHOLOGY, 2024, 19 (01)
  • [28] Real-world PD-L1 test utilization and analytical concordance of the PD-L1 IHC 28-8 and 22C3 assays in patients with breast cancer
    Mitra, Shreya
    Prince, Emily A.
    Pratt, James
    Novotny, James, Jr.
    Chizhevsky, Vladislav
    Ragheb, Josette William
    Huron, David
    CANCER RESEARCH, 2021, 81 (04)
  • [29] PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy
    Ahn, Soomin
    Kim, Kyoung-Mee
    MODERN PATHOLOGY, 2021, 34 (09) : 1719 - 1727
  • [30] High staining reproducibility and scoring precision demonstrated in endometrial cancer stained with PD-L1 IHC 22C3 pharmDx used in conjunction with combined positive score
    Hand, Julia
    Morones, Amber
    Moquin, Deanna
    Martyniuk, Kelly
    Kalpakoff, Megan
    Tabuena-Frolli, Siena
    Milo, Jay
    Hund, Stephanie
    CANCER RESEARCH, 2024, 84 (06)
12345